Search Results - "Theelen, Willemijn"

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer by Mok, Tony S, Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina C, Kim, Hye R, Ramalingam, Suresh S, Shepherd, Frances A, He, Yong, Akamatsu, Hiroaki, Theelen, Willemijn S.M.E, Lee, Chee K, Sebastian, Martin, Templeton, Alison, Mann, Helen, Marotti, Marcelo, Ghiorghiu, Serban, Papadimitrakopoulou, Vassiliki A

“…In a randomized trial involving patients with non–small-cell lung cancer with mutant EGFR (T790M) in whom a tyrosine kinase inhibitor had failed, osimertinib…”
Get full text

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials by Theelen, Willemijn S M E, Chen, Dawei, Verma, Vivek, Hobbs, Brian P, Peulen, Heike M U, Aerts, Joachim G J V, Bahce, Idris, Niemeijer, Anna Larissa N, Chang, Joe Y, de Groot, Patricia M, Nguyen, Quynh-Nhu, Comeaux, Nathan I, Simon, George R, Skoulidis, Ferdinandos, Lin, Steven H, He, Kewen, Patel, Roshal, Heymach, John, Baas, Paul, Welsh, James W

“…Radiotherapy might augment systemic antitumoral responses to immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic…”
Get full text

IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer by Blomberg, Olga S., Spagnuolo, Lorenzo, Garner, Hannah, Voorwerk, Leonie, Isaeva, Olga I., van Dyk, Ewald, Bakker, Noor, Chalabi, Myriam, Klaver, Chris, Duijst, Maxime, Kersten, Kelly, Brüggemann, Marieke, Pastoors, Dorien, Hau, Cheei-Sing, Vrijland, Kim, Raeven, Elisabeth A.M., Kaldenbach, Daphne, Kos, Kevin, Afonina, Inna S., Kaptein, Paulien, Hoes, Louisa, Theelen, Willemijn S.M.E., Baas, Paul, Voest, Emile E., Beyaert, Rudi, Thommen, Daniela S., Wessels, Lodewyk F.A., de Visser, Karin E., Kok, Marleen

“…Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on…”
Get full text

Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect by Theelen, Willemijn SME, de Jong, Monique C, Baas, Paul

“…•Immune checkpoint inhibitors are the new cornerstone of metastatic NSCLC treatment.•Several tumor immune escape mechanisms causing failure to ICIs have been…”
Get full text

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC by Hummelink, Karlijn, van der Noort, Vincent, Muller, Mirte, Schouten, Robert D, Lalezari, Ferry, Peters, Dennis, Theelen, Willemijn S M E, Koelzer, Viktor H, Mertz, Kirsten D, Zippelius, Alfred, van den Heuvel, Michel M, Broeks, Annegien, Haanen, John B A G, Schumacher, Ton N, Meijer, Gerrit A, Smit, Egbert F, Monkhorst, Kim, Thommen, Daniela S

“…Durable clinical benefit to PD-1 blockade in non-small cell lung cancer (NSCLC) is currently limited to a small fraction of patients, underlining the need for…”
Get full text

A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics by Hummelink, Karlijn, Tissier, Renaud, Bosch, Linda J W, Krijgsman, Oscar, van den Heuvel, Michel M, Theelen, Willemijn S M E, Damotte, Diane, Goldwasser, François, Leroy, Karen, Smit, Egbert F, Meijer, Gerrit A, Thommen, Daniela S, Monkhorst, Kim

“…Because PD-1 blockade is only effective in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), biomarkers are needed to guide…”
Get full text

Going Beyond Results of the PEMBRO-RT Trial-Reply by Theelen, Willemijn S M E, Baas, Paul

Get more information

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination by van der Woude, Lieke L, Gorris, Mark A J, Wortel, Inge M N, Creemers, Jeroen H A, Verrijp, Kiek, Monkhorst, Kim, Grünberg, Katrien, van den Heuvel, Michel M, Textor, Johannes, Figdor, Carl G, Piet, Berber, Theelen, Willemijn S M E, de Vries, I Jolanda M

“…BackgroundImmunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients…”
Get full text

Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images by van Eekelen, Leander, Spronck, Joey, Looijen-Salamon, Monika, Vos, Shoko, Munari, Enrico, Girolami, Ilaria, Eccher, Albino, Acs, Balazs, Boyaci, Ceren, de Souza, Gabriel Silva, Demirel-Andishmand, Muradije, Meesters, Luca Dulce, Zegers, Daan, van der Woude, Lieke, Theelen, Willemijn, van den Heuvel, Michel, Grünberg, Katrien, van Ginneken, Bram, van der Laak, Jeroen, Ciompi, Francesco

“…Programmed death-ligand 1 (PD-L1) expression is currently used in the clinic to assess eligibility for immune-checkpoint inhibitors via the tumor proportion…”
Get full text

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer by Theelen, Willemijn S M E, Kuilman, Thomas, Schulze, Katja, Zou, Wei, Krijgsman, Oscar, Peters, Dennis D G C, Cornelissen, Sten, Monkhorst, Kim, Sarma, Pranamee, Sumiyoshi, Teiko, Amler, Lukas C, Willems, Stefan M, Blaauwgeers, Johannes L G, van Noesel, Carel J M, Peeper, Daniel S, van den Heuvel, Michel M, Kowanetz, Marcin

“…In non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both TC and tumor-infiltrating immune cells (IC) is currently the most…”
Get full text

Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice? by Theelen, Willemijn S. M. E., Baas, Paul

Get full text

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer by Theelen, Willemijn SME, Mittempergher, Lorenza, Willems, Stefan M, Bosma, Astrid J, Peters, Dennis DGC, van der Noort, Vincent, Japenga, Eva J, Peeters, Ton, Koole, Koos, Šuštić, Tonći, Blaauwgeers, JL, van Noesel, Carel J, Bernards, René, van den Heuvel, Michel M

“…This study aimed to determine protein expression levels of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in early stage non‐small cell lung cancer…”
Get full text

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial by Shepherd, Frances A., Papadimitrakopoulou, Vassiliki, Mok, Tony, Wu, Yi-Long, Han, Ji-Youn, Ahn, Myung-Ju, Ramalingam, Suresh S., John, Tom, Sebastian, Martin, Theelen, Willemijn, Laus, Gianluca, Collins, Barbara, Markovets, Aleksandra, Thress, Kenneth S., Oxnard, Geoffrey R.

“…Abstract only…”
Get full text

Abstract 1662: Immunogenomic mechanisms of response and resistance to combined radiation and immunotherapy in lung cancer by Belcaid, Zineb, Theelen, Willemijn S., White, James R., Sivakumar, Ashok, Balan, Archana, Niknafs, Noushin, Ferreira, Leonardo, Adleff, Vilmos, Velculescu, Victor E., Baas, Paul, Karchin, Rachel, Anagnostou, Valsamo

“…Introduction: Radiation therapy (RT) has the potential to elicit a systemic immune response beyond the field of radiation (abscopal effect), which can be…”
Get full text

Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study by Theelen, Willemijn, H.Peulen@Nki.Nl, No Firstname, Lalezari, Ferry, de Vries, Jeltje, De Langen, Joop, Aerts, Joachim, Monkhorst, Kim, Baas, Paul

“…Abstract only…”
Get full text

Abstract 1184: Combination pembrolizumab and radiotherapy induces anti-tumor immune responses in immunologically-cold non-small cell lung cancer by Huang, Justin, Theelen, Willemijn S., Belcaid, Zineb, Najjar, Mimi, Cherry, Christopher, Balan, Archana, White, James R., Niknafs, Noushin, Wehr, Jaime, van den Heuvel, M.M., Karchin, Rachel, Baas, Paul, Velculescu, Victor E., Anagnostou, Valsamo

“…Introduction: Primary resistance to immune checkpoint inhibition (ICI) is in part driven by a “cold” tumor microenvironment in the context of low PD-L1…”
Get full text

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN[gamma] signaling in non-small cell lung cancer by Theelen, Willemijn S. M. E, Kuilman, Thomas, Schulze, Katja, Zou, Wei, Krijgsman, Oscar, Peters, Dennis D. G. C, Cornelissen, Sten, Monkhorst, Kim, Sarma, Pranamee, Sumiyoshi, Teiko, Amler, Lukas C, Willems, Stefan M, Blaauwgeers, Johannes L. G, van Noesel, Carel J. M, Peeper, Daniel S, van den Heuvel, Michel M, Kowanetz, Marcin

“…Background In non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both TC and tumor-infiltrating immune cells (IC) is currently…”
Get full text

Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDClung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC by Theelen, Willemijn, Perol, Maurice, Cuppens, Kristof, Demedts, Ingel, Borm, Frank, Biesma, Bonne, Wauters, Els, Colinet, Benoit, Buchmeier, Eva-Lotte, Althoff, Friederike, Pons-Tostivint, Elvire, Van de Kerkhove, Charlotte, Moro-Sibilot, Denis, Sibille, Anne, Derijcke, Sofie, Skrzypski, Marcin, Plumas, Joel, De Vos, Beatrice, Debruyne, Channa, Cantero, Frederique, Adriaenssens, Stefanie, Renard, Florence, Vansteenkiste, Johan

“…Background PDC*lung01 (IMP) is a therapeutic cancer vaccine based on an irradiated plasmacytoid dendritic cell line loaded with HLA-A*02:01-restricted peptides…”
Get full text

Abstract 1182: PDClung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer by Plumas, Joel, Sibille, Anne, Demedts, Ingel, Pons-Tostivint, Elvire, Van de Kerkhove, Charlotte, Derijcke, Sofie, Theelen, Willemijn, Biesma, Bonne, Borm, Frank, Wauters, Els, Collodoro, Mike, Badawy, Kays Al, Duchayne, Camille, Debruyne, Channa, Devos, Beatrice, Colinet, Benoit, Moro-Sibilot, Denis, Perol, Maurice, Buchmeier, Eva-Lotte, Skrzypski, Marcin, Cuppens, Kristof, Vansteenkiste, Johan

“…We have developed an innovative cancer vaccine for the treatment of advanced NSCLC patients in combination with checkpoint inhibitors. This PDC*lung01 product…”
Get full text

Molecular pathology in tumour classification: the present and future molecular revolution by Willems, Stefan M, Engelsman-Theelen, Willemijn, Blaauwgeers, J L G Hans

“…The way we classify somatic diseases changes rapidly. Whereas at one time examination by the naked eye was used as a guide and then microscopy was used to view…”
Get more information